Download - Courtallam ima gynec onco ppt

ROLE OF CHEMOTHERAPY IN

GYNAEC MALIGNANCIES

DR. R. RAJKUMAR M.D., D.M.

OVARIAN CANCER

Leading cause of death from gynecologic cancer

75% present in advanced stage

Improvement in 5yr survival –

36% in 1977

39% in 1986

45% in 2002

More effective chemotherapy options

Surgical techniques

OVARIAN CANCER – CLINICAL

FINDINGS

Usual features :

Abdomino –pelvic mass, ascites, left supraclavicular

lymph node

Unusual presentations:

Right supraclavicular or axillary lymph nodes with

abdominal mass

Isolated pleural effusion

Isolated ascites without any ovarian mass

OVARIAN CANCER - EVALUATION

Detailed history and clinical exam

Pelvic exam including per rectal exam to assess POD

- EUA

Endometrial biopsy in selected cases

Complete blood counts

Renal function tests

Liver function tests

Tumor markers

Chest x ray & other imaging studies

Genetic counseling

OVARIAN CANCER - EVALUATION

Tumor markers:

CA 125 –most commonly elevated in 80% of serous tumors

not elevated in 50% of early stage tumors, mucinous and clear cell carcinomas

Not a reliable diagnostic test

Post operatively ca125 levels –sensitive –to monitor response to chemo

Normalization after 3 cycles –favorable outcome

Nadir <10u/ml – favorable

Useful in follow up for detecting recurrence

CEA , CA 19-9 - mucinous tumors & in krukenbergs tumor

OVARIAN CANCER – TUMOR

MARKERS

Sr.VEGF levels

HE4 (human epididymis 4)-WFDC gene product

MCS-F in serum & ascitic fluid

Proteomic spectral analysis of serum

SELDI-TOF –MS : Surface enhanced laser desorption

and ionization time of flight MS

OVARIAN CANCER - IMAGING

USG abdomen with colour doppler study –

transvaginal sonography

Complex mass with increased vascularity

Ascites

Enlarged para aortic nodal masses

Omental and peritoneal deposits larger than 1cm

Matted bowel loops

Ultrasonography &

Colour Doppler


CT SCAN abdomen & pelvis:

Extent of disease in upper abdomen

Helps to decide on primary surgery or neoadjuvant chemotherapy

Attachment of omentum to splenic hilum

Disease/tumor nodules >2cm in mesentery, liver surface or parenchyma,

diaphragm, gall bladder fossa, suprarenal para aortic nodes

Pulmonary or pleural nodules

CT Scan


MRI abdomen – not superior to CTscan except in pregnant

women where USG is inconclusive

PET-CT scan : not for diagnosis

Useful in rec.disease with isolated CA125 elevation

OVARIAN CANCER - INVESTIGATIONS

UPPER GI SCOPY& COLONOSCOPY – NOT

INDICATED ROUTINELY

Symptoms s/o gastric disease or lower GI symptoms or fecal

occult blood positive

4% have associated GI malignancy

Mammography

Genetic counseling in pts with positive family history

EPITHELIAL OVARIAN

CANCER

DIAGNOSISSymptoms

Clinical Examination

Investigations

Ca125 Imaging

USG Colour Doppler CT/MRI

FNAC contraindicated

OVARIAN CANCER STAGING

Stage I - Limited to ovaries

A. Unilateral ovary

B. Bilateral ovaries

C. Positive cytology

Stage II - Limited to pelvis

A. Extends to uterus or tubes

B. other pelvic organs

C. Positive cytology

Stage III – Spread to upper abdomen or regional lymph nodes

A. Microscopic spread

B. Macroscopic < 2 cm

C. Macroscopic > 2 cm

Stage IV - Spread outside peritoneum, pleura or parenchymalliver metastases

OVARIAN CANCER

FIGO STAGING SYSTEM

Stage Description Incidence Survival

I Confined to ovaries 20% 73%

II Confined to pelvis 5% 45%

III Confined to abdomen/ 58% 21%lymph nodes

IV Distant metastases 17% <5%

Jelic S, et al. Program and abstracts of the 27th Congress of the European

Society for Medical Oncology; 2002; Nice, France.

Mocharnuk R. Medscape Web site.

http://www.medscape.com/viewarticle/444134. Accessed May 2, 2007.

FIGO = International

Federation of Gynecology

and Obstetrics

HOW TO PROCEED AFTER

INVESTIGATIONS ?

Decision to proceed directly to surgery is a clinical one – in

advanced stage :

based on extent of disease

Performance status

Nutritional status

Comorbid illness

HOW TO PROCEED AFTER

INVESTIGATIONS?

Operable tumors – laparotomy and proceed

Avoid percutaneous FNA of localised masses

or complex cysts – upstage disease

WHO NEEDS NEOADJUVANT

CHEMOTHERAPY?

Presence of gross ascites,

huge fixed pelvi-abdominal mass,

nodules in POD

PS III-IV

Supraclavicular nodes

Pleural effusion – bilateral

USG abdomen showing

extensive peritoneal,omental deposits and liver

sec, bilateral pleural effusion

CT SCAN FINDINGS

Diffuse peritoneal thickening(DPT) >4mm – involving

atleast 2 of the 5 areas

lateral colic gutters

Lateral conal fascia

Anterial abdominal wall

Diaphragm and splenic peritoneal reflection

Sean C.Dowdy et al, CANCER - 2004

FOR NEOADJUVANT CHEMOTHERAPY

Cytologic evidence of malignancy – ascitic fluid

FNA of the mass ( transvaginal –preferably)

Laparoscopy before NACT:

- to assess disease extent and for biopsy in cases

where repeated cytology is negative for malignancy

OVARIAN CANCER SURGICAL

DEBULKING AND STAGING

Exploration

Washings/

Ascites

(Staging)

TAH/

BSO

Biopsies

(Staging)

Goals (Debulking)•Assessment of extent of disease

•Optimal tumor reduction

TAH = total abdominal hysterectomy

BSO = bilateral salphingo-oophorectomy

Cytoreductive Surgery

Goal is elimination of all tumor

• No gross residual (microscopic)

• Optimal (<1 cm)

• Suboptimal (>1 cm)

Operative Technique

• Resection of urinary or intestinal tract

Surgical Outcomes

• Optimal in ~75% of cases

• Does it matter?

Does Cytoreduction Matter?

Optimal Suboptimal

Response Rate

Clinical CR 95% 75%

Pathologic CR 50% 25%

Progression free interval (mo) 34 13

Survival (mo) 50 36

10-yr survival 35% 15%

PROGNOSTIC FACTORS

Volume of residual disease after surgery

Stage

Histologic subtype

Histologic grade

Performance status

Age

Ovarian cancer prognostic profile(OCPP)

Chemotherapy response profile (CRP)

Gene expression profiling

PRIMARY TREATMENT OF OVARIAN CANCER

1995 1997 1999

Cyclophosphamide +

Cisplatin

STANDARD OF CARE

GOG 111 establishes Taxol-CDDP

as standard 1st line

2001

GOG 158 shows Taxol-carboplatin = Taxol-

CDDP, with improved toxicity and QoL

GOG 178 demonstrates improved DFS with

longer duration of maintenance Taxol – No

data on overall survival

GOG 172 confirms IP

therapy leads to a survival

advantage compared with IV

NEW STANDARD OF CARE?

SWOG 8501 demonstrates improved

survival with IP therapy

2003 2005 2008

GOG 182 demonstrates

no survival advantage

to triplet or sequential

doublet therapy

FIRST-LINE THERAPY –

Standard Treatment Options

Platinum + Taxane Chemotherapy

(Carboplatin + Paclitaxel)

Surgery with maximum

cytoreduction effort <1cm

residual disease

CHEMOTHERAPY

• Standard front-line chemotherapy today is carboplatin, AUC 6 to 7.5, paclitaxel 175 mg/m2 every 21 days for 6 cycles

• Result of several studies over last decade

– GOG 1111 and OV 102 - paclitaxel/cisplatinvs cyclophosphamide/cisplatin

– GOG 1583 and AGO OVAR-34 - carboplatininstead of cisplatin

1. McGuire WP, et al. N Engl J Med. 1996;334(1):1-6.

2. Piccart MJ, et al. J Natl Cancer Inst. 2000;92(9):699-708.

3. Ozols RF, et al. J Clin Oncol. 2003;21(17):3194-3200.

4. du Bois AD, et al. J Natl Cancer Inst. 2003;95(17):1320-1329.

GOG = Gynecologic Oncology Group

AGO = Arbeitsgemeinschaft

Gynaekologische Onkologie

The Role of Paclitaxel in First-line

Therapy for Ovarian CarcinomaStudy # Pts Regimen

Median PFS

(mo)

Median OS

(mo)

GOG

1321

377

III suboptimal-IV

Cisplatin/

Paclitaxel (24 h) x 614.1 26.3

Cisplatin 100 mg/m2 x 6 16.4 30.2Paclitaxel 200 mg/m2 (24 h)* 10.8 25.9

ICON

32

2074

I-IV

Carboplatin/

Paclitaxel (3 h)17.3 36.1

Carboplatin or CAP 16.1 35.4

CAP = cyclophosphamide, doxorubicin, cisplatin

GOG = Gynecologic Oncology Group

ICON = International Collaborative Ovarian Neoplasm Group

OS = overall survival

PFS = progression-free survival

1. Muggia FM, et al. J Clin Oncol. 2000;18(1):106-115.

2. International Collaborative Ovarian Neoplasm Group. Lancet. 2002;360(9332):505-515.

*CR/PR rates on paclitaxel

monotherapy (42%) vs cisplatin

regimens (67%), P <.001

OVARIAN CARCINOMA: CLINICAL COURSE

Symptoms

Diagnosis

Chemotherapy #1

Staging

Primary cytoreduction

Interval

Cytoreduction

Progression

Chemo #2 Chemo #3+

Supportive

Care

Death

Consolidation/

Maintenance

Cure

Secondary

CytoreductionSecond-Look

EPITHELIAL OVARIAN CANCER

PLAN OF MANAGEMENT

Resectable

Primary cytoreductive surgery (Max)

Chemo 6 cycles

Unresectable

Chemo 3 cycles

Interval cytoreductive Surgery (Max)

Chemo 3 cycles

Stage III/IV

CHEMOTHERAPY – EARLY STAGE

DISEASE

High risk early stage:

stage I, gr III, Ic,any stage II

Stage Ia,Ib –gr I & II can be observed

ICON I(International Collborative Ovarian Neoplasm Trial I) &

ACTION (Adjuvant Chemotherapy in Ovarian Neoplasm Trial) –chemo improves progression free & OS in high risk early stage disease(925 pts – os– superior for platinum based chemo

GOG study -3 vs 6 cycles – 33% reduction in risk of rec in high risk disease who received 6cycles of chemo

Patients with suboptimal surgery benefit from platinum based chemo

Chemotherapy in advanced stage

GOG 111: paclitaxel+cisplatin superior to cisplatin + cyclophosphamide

RR 73% vs 60%

Median PFS 18 vs 13mo

Median os 38mo vs 24mo p<001

60mo of follow up – 20% reduct. In risk of progression & 34% reduction in risk of death

OV10,ICON 3

GOG 132 –sequential administration of pacli or cisplatin is therapeutically equivalent

Chemotherapy in advanced stage

GOG 158,AGO,NETHERLANDS-DENMARK:

Carboplatin+paclitaxel vs cisplatin +paclitaxel is equivalent – PFS &OS

Carbo+paclitaxel – preferred – favorable toxicity profile

Reduced emesis,neutropenia,nephrotoxicity

Short infusion time

Marginal PS,Comorbid medical condition – start with single agent carboplatin – add paclitaxel later

No benefit for 12 vs 6 cycles

No benefit for addition of 3rd cytotoxic agent – PLD,EPI,TOPO,GEM

Addition of bevacizumab

Interventions to Mortality?

Time

Dis

ea

se

Vo

lum

e

Prevention

Screening

Current point of diagnosis

and initiation of treatment

Prevention

– Pedigree Analysis

– Medical: Oral Contraceptives

– Surgical: Risk-Reducing Oophorectomy

Screening

– Pelvic Examination

– Ultrasonography

– CA125 and other (OvaSure) Serum Testing

– Proteomics (OvaCheckTM)

Interventions to Mortality?

NIH Consensus Development Panel

“…there is no evidence available yet

that the current screening modalities

of CA 125 and ultrasonography can

be effectively used for widespread

screening to reduce mortality from

ovarian cancer…”

Screening – US and CA 125

Goals of Treatment:

Relapsed Ovarian Cancer• Prolong Survival

• Delay Time to Progression

• Control Disease-Related Symptoms

• Minimize Treatment-Related Symptoms

• Maintain or Improve Quality of Life

Surveillance Options for Ovarian

Cancer Patients in Remission• Second-look laparotomy

• Physical examination

– Include pelvic examination

• CA-125

• Imaging

– CT scan

– MRI?

– PET scan?CT = computed tomography

MRI = magnetic resonance imaging

PET = positron emission tomography

Ovarian Cancer:

How is Relapse Defined?• Continuous rise in CA-125

• CA-125 above 100

• Radiographic recurrence

• Symptomatic recurrence

• Physical examination findings

• Combination of above

Effect of Platinum-Free Intervalon Response Rate

% Response to Second-line

Platinum Therapy

Platinum-Free

Interval (mos)Markman Gore Blackledge

0-617%

10%

7-12 27% 29%

13-1833% 27%

63%

19-24 94%

>24 59% 57%

Non-Platinum

Therapy

15%

20%

30%

30%

Markman M, et al. J Clin Oncol. 1991;9(3):389-393.

Gore ME, et al. Gynecol Oncol. 1990;36:207-211.

Blackledge G, et al. Br J Cancer. 1989;59:650-653.

Refractory

PRIMARY

TREATMENT

Resistant

Sensitive

0 3 6 12 18 24

Months

“Very Sensitive”

Ovarian Cancer at First Relapse

Definition of Sensitivity

Defined as measurable recurrence, not biochemical (CA-125) recurrence

Active Agents in Ovarian CancerFDA approved

Altretamine Carboplatin Cisplatin

Gemcitabine/

Carboplatin

Paclitaxel Pegylated liposomal

doxorubicin

Topotecan

Not FDA approved, compendium listed

Chlorambucil Cyclophosphamide Docetaxel

Doxorubicin Epirubicin Etoposide

5-FU/LV Gemcitabine Ifosfamide

Irinotecan Melphalan Methotrexate

Thiotepa Vinorelbine

Not FDA approved, not compendium listed

Aromatase inhibitors Bevacizumab Pemetrexed

Tamoxifen

Secondary

Cytoreduction• Controversial

• Inconsistent definitions

• Benefit appears confined to patients likely to respond to additional chemo:

• >12 month PFI

• Isolated site of recurrence

• Disease completely resectable Kidney

Resected LiverDiaphragm

Kidney

Vena Cava

Tumor Mass

Renal Vein

PFI = progression-free interval

Advanced Ovarian Cancer

cisplatin paclitaxelmulti-drugAlkeran

Median Survival: 1975 - 2005

IP therapy

(optimal)(optimal)

mon

ths

12 1424

37

5257

66

0

20

40

60

80

1975 1983 1986 1996 1998 2003 2005

The tumor extends to the pelvic wall and/or involves lower third of the vagina and or causes hydronephrosis or non-functioning kidney**

Stage IIIA: Tumor involves lower third of the vagina, with no extension to the pelvic wall

Stage IIIB: Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney

The carcinoma is strictly confined to the cervix

(extension to the corpus would be disregarded)

Stage IA: Invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion ≤5 mm and largest extension ≤7 mm

Stage IA1: Measured stromal invasion of ≤3.0 mm in depth and extension of ≤7.0 mm.

Stage IA2: Measured stromal invasion of >3.0 mm and ≤5.0 mm with an extension of not >7.0 mm

Stage IB: Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA*

Stage IB1: Clinically visible lesion ≤4.0 cm in greatest dimension

Stage IB2: Clinically visible lesion >4.0 cm in greatest dimension

The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum.

A bullous edema, as such, does not permit a case to be allotted to Stage IV

Stage IVA: Spread of the growth to adjacent organs.

Stage IVB: Spread to distant organs.

Stage II

Stage I

FIGO staging system, 2009

Cevical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina

Stage IIA: Without parametrial invasion

Stage IIA1: Clinically visible lesion ≤4.0 cm in greatest dimension

Stage IIA2: Clinically visible lesion >4 cm in greatest dimension

Stage IIB: With obvious parametrial invasion

Stage III

Stage IV

*All macroscopically visible lesions—even with superficial invasion—are allotted to stage IB carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.00 mm and a horizontal

extension of not >7.00 mm. Depth of invasion should not be >5.00 mm taken from the base of the epithelium of the original tissue—superficial or glandular. The depth of invasion should always be reported

in mm, even in those cases with “early (minimal) stromal invasion” (~1 mm). The involvement of vascular/lymphatic spaces should not change the stage allotment.** On rectal examination, there is no cancer-free space between the tumor and the pelvic wall. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to

another cause.

Diagnosis is based on conization!

Recommended work-up

• Vaginal and rectal examination, exfoliative cytology (Papanicolaou smear), colposcopy, biopsy and/or endocervical curettage (ECC), conization or Loop electrosurgical procedure (LEEP)

• Histopathological finding with all standard tumor parameters

• Laboratory analyses: WBC, biochemical analyses

• Imaging: Chest X-ray, pelvic and abdominal ulstrasound

ConizationNecessary HP parameters:2

• Depth of invasion

• Width of the tumor

• Tumor differentiaion

• Lympho-vascular space invasion (LVSI)

• Resection margins

Margins and/or

ECC positive for dysplasia

Margins clear

ECC negative

Stage Ia1

LVSI negative

•Stage Ia1 with extensive LVSI

Stage Ia2

• Repeated conisation

• Modified radical hysterectomy (type B6) if re-conisation is not possible

± pelvic lymphadenectomy

Conization if preservation of fertility is desired

or

Simple (extrafascial, type A6) hysterectomy with or

without salpingoophorectomy

Conization or radical trachelectomy if preservation of fertility is desired

or

Modified radical hysterectomy (type B6)

and

Pelvic lymphadenectomy

Recommended follow-up

Every 3 months after completed therapy during the first year; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination, including cytology

and colposcopy, should be performed depending on symptoms, local findings and general condition of the patient

Cervical cancerFIGO Stage I a

Microinvasive carcinoma (invasion ≤ 5 mm)

Recommended work-upNeccessary investigations:

• Vaginal and rectal examination, colposcopy, biopsy and/or endocervical curettage (ECC); conization or loop electrosurgical procedure (LEEP) if needed for definitive diagnosis


• Laboratory analyses: WBC, biochemical analyses including check for renal function and Hb

• Imaging: Chest X-ray, abdominal and pelvic ultrasound (size and position of the tumor and tumor volume/cervix ratio)

Optional investigations:

Pelvic NMR, CT of the abdomen (PET/CT if possible), cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of the bladder or rectum should be confimed histologically

Radical surgery

• Uterus with paracervical tissues and upper part of vagina (radical, type C6 hysterectomy) + pelvic lymphadenectomy

or

• Entire cervix with paracervical tissues (radical trachelectomy) if fertility is desired + pelvic lymphadenectomy

or

• Upper part of vaginal cuf, paracervical tissues + pelvic lymphnodes in case of previous simple hysterectomy

* At least 2 cm distance from the resection margins is desirable

** In premenopausal women ovaries can be retained; if so tranposition is advised.

*** For the desision of further management, all neccesary histopathologic parameters4 should be requested

Chemo-radiation

Neoadjuvant chemotherapy followed by radiation or surgery is an option for locally advanced

tumors (Ib2 and IIa2) but awaits confirmatory evidence from controlled clinical trials.


Every 3 months after completed therapy during the first year; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination should be performed

depending on symptoms, local findings and general condition of the patient

• Positive resection margins

• Involvement of parametria

• Residual tumor

• Multiple positive nodes (>3)

• Positive nodes (1-3)

• Poorly differentiated or undifferentiated tumor (G3)

• LVSI present

• Primary tumor

(tumor-cervix volume) >3 cm

• Endocervical invasion

(barrel shaped cervix)

• Inadequate surgery

• Insufficient HP (if report of all necessary parts is missing)

• Medical contra-indications for surgery

• Ib2/IIa2 tumors in selected cases

• Anterior vaginal extension

• Invasive cancer after simple hysterectomy

• Choice of the patient

Concomitant

Chemo-radiation

Radiation

± Chemotherapy

Radiation

± ChemotherapyFollow up

Negative nodes

GOG score*

*consider using GOG score as a guide for adjuvant treatment5

Low risk

(GOG score < 120)

Low risk

(GOG score < 120)

or

Cervical cancerFIGO Stage Ib - IIa

Squamocellular, Adenocarcinoma, Adenosquamous

Recommended work-up• Vaginal and rectal examination, biopsy or endocervical curettage (ECC)



• Imaging: Chest X-ray, abdominal and pelvic ultrasound

• Pelvic NMR, CT of the abdomen (PET/CT if possible), cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of the bladder or rectum should

be confimed histologically


Every 3 months after completed therapy; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination should be performed depending on

symptoms, local findings and general condition of the patient

Pelvic MRI and

Abdominal CT

Paraaortic nodes (PALN) negative

(=not enlarged)

Pelvic or paraaortic nodes (PALN)

positive (enlarged ≥2 cm))

Pelvic (± paraaortic) radiation

+ brachytherapy

+ concomitant chemotherapy

CT of the lungs & mediastinum

CT negative CT positive

Pelvic radiation (with paraaortic if PALN are positive) + brachytherapy + concomitant chemotherapy

* Consider:

• resection of adnexal mass and/or extraperitoneal resection of enlarged nodes

• Sequential chemoth and Concomitant ChemoRadioTherapy /External Beam RadioTherapy (CCRT/EBRT)

Palliative pelvic RT

± Palliative chemotherapy

*Stage IVa• with vesicovaginal fistula: if pelvic, abdominal and chest imaging exclude distant metastases primary pelvic exenteration can be considered

• NACT may be offered to large bulky tumors to downsize tumor prior to CCRT

Cervical cancerFIGO stage IIb- IV

Recommended work-up•• Vaginal and rectal examination, biopsy - histopathological confirmation of recurrence


• Imaging: Chest X-ray, pelvic and abdominal ultrasound, pelvic NMR and CT of the lungs and abdomen; (PET/CT if possible)

• Cystoscopy, rectoscopy, IVU or sonographic renal examination


Every 3 months for two years or more often if clinically indicated. Every 4-6 months thereafter. Annually afterwards. Investigations in addition to gynaecological examination should be

performed depending on symptoms, local findings and general condition of the patient

Lungs & abdominal CT

Pelvic recurrence Extrapelvic recurrence

Options include:

• Palliative radiotherapy or chemo-radiation

• Systemic therapy

• Supportive care

* Resection in selected cases

(in particular paraaortic nodes)

may be considered

Previous radiationNo previous radiation

Options include:

• Chemo-radiation

• Neoadjuvant chemotherapy (NACT)

• Supportive care

Central pelvic

recurrence

Sidewall pelvic

recurrence

Options include

• Radical hysterectomy in tumor <2 cm

• Pelvic exenteration

• Neoadjuvant chemotherapy (NACT) + surgery

Other options if surgery is not possible:

• Re-irradiation

• Neoadjuvant chemotherapy (NACT) + radiation


• Supportive care

Options include:

• Resection of isolated disease


• Supportive care

Cervical cancer- recurrence -

Recommended work-upNeccessary investigations:

• Vaginal and rectal examination, colposcopy, biopsy and/or endocervical curettage (ECC); conization or loop electrosurgical procedure (LEEP) if needed for definitive diagnosis


• Laboratory analyses: WBC, biochemical analyses including including check for renal function and Hb

• Imaging: Chest X-ray, abdominal and pelvic ultrasound (size and position of the tumor and tumor volume/cervix ratio)

Optional investigations:

• Pelvic NMR, CT of the abdomen (PET/CT if possible), cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of the bladder or rectum should be confirmed histologically

*Stage of the disease is determined using FIGO classification1


Every 3 months after completed therapy during the first year; every 6 months up to 5 years. Annually afterwards. Investigations in addition to gynaecological examination

should be performed depending on symptoms, local findings and general condition of the patient

FIGO Ia FIGO Ib-IIa FIGO IIb-IV

• Diagnosis is based on conization;

resection margins should be clear

• Further decision depends on the

presence of poor histologic prognostic

factors2

Surgery Chemo-radiation Concomitant chemoradiation

or

Radical radiation only if unfit for

chemotherapy

* Stage IV1 with vesicovaginal fistula: if

pelvic, abdominal and chest CT exclude

distant metastases, primary pelvic

exenteration can be considered

• Medical contra-indications for surgery

• Ib2/IIa tumors

• Anterior vaginal extension

• Invasive cancer after simple hysterectomy

• Choice of the patient

• Radical hysterectomy (type C6)

or

• Radical trachelectomy

or

• Resection of the upper part of vagina and parametrectomy in case of previous

simple hysterectomy

and

• Pelvic lymphadenectomy

* Decision about further therapy is based on the presence of adverse histological

factors

Neoadjuvant chemotherapy followed by

radiation or surgery is an option for locally

advanced tumors, but awaits confirmatory

evidence from controlled clinical trials.

FIGO Ia1

LVSI negative

• Conization/radical

trachelectomy

or

• Modified radical

hysterectomy(type B6)

and

• Pelvic Lymphadenectomy

• Conization

or

• Simple hysterectomy

(type A6)

Follow-up No adverse prognostic factors Adverse prognostic factors4 present

Follow-up Adjuvant therapy

(Radiation ± Chemotherapy)

FIGO Ia1, LVSI

positive

or

Cervical cancerSquamocellular, Adenocarcinoma,

Adenosquamous

Why are YOU here ???

Why am I here ???

Why are WE here ???

Download - Courtallam ima gynec onco ppt

Top Related